ATORvastatin in Pulmonary TUBerculosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

March 30, 2026

Study Completion Date

September 30, 2026

Conditions
Pulmonary TuberculosisTuberculosisKoch's Disease
Interventions
DRUG

Atorvastatin 20mg

Participants will receive oral atorvastatin 20mg daily for 16 weeks

DRUG

Atorvastatin 40mg

Participants will receive oral atorvastatin 40mg daily for 16 weeks

DRUG

Atorvastatin 60mg

Participants will receive oral atorvastatin 60 mg daily for 16 weeks

DRUG

Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)

Participants will receive 8 weeks of daily oral treatment with rifampin, isoniazid, pyrazinamide, ethambutol, followed by 16 weeks of daily oral treatment with rifampin, isoniazid

Trial Locations (8)

2345

RECRUITING

Bowen University Teaching Hospital, Iwo

Unknown

RECRUITING

National Tuberculosis Reference Laboratory, Zaria

RECRUITING

Federal Teaching Hospital, Katsina

RECRUITING

Federal Medical Center, Keffi

RECRUITING

Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife

RECRUITING

University College Hospital, Ibadan

RECRUITING

Usman Danfodio University, Sokoto

RECRUITING

University of Abuja Teaching Hospital, Gwagwalada

All Listed Sponsors
collaborator

Open Philanthropy

OTHER

lead

Obafemi Awolowo University Teaching Hospital

OTHER